Entheon Biomedical Corp.

Entheon Biomedical Corp. (OTCQB: ENTBF) announced a non-brokered private placement financing for up to 30,000,000 Units at a price of CDN$0.10 per unit, for gross proceeds of up to CDN$3,000,000. Each unit will consist of one common share in the capital of the company and one...

Entheon Biomedical Corp. announced the launch of a psychedelics genetic test kit last week through its wholly owned subsidiary HaluGen Life Sciences Inc. The launch represents the first revenue stream for the company, said CEO Timothy Ko. The test will serve as a pre-screening platform...

Entheon Biomedical Corp. (OTC: ENTBF) a company dedicated to the application of the psychedelic DMT in the treatment of addiction, announced the launch of a psychedelics genetic test kit, through its wholly-owned subsidiary, HaluGen Life Sciences Inc. The test will serve as a pre-screening...

Compass Launches Center Of Excellence Compass Pathways (NASDAQ: CMPS) officially launched the Centre of Excellence, in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland. This “clinic model” will study and...

Numinus and MAPS Collaborate to Study MDMA in Canada Numinus Wellness (TSXV: NUMI) and the MAPS Public Benefit Corporation have joined forces to bring MDMA-assisted psychotherapy through clinical trials for approval in Canada. The pair will first seek permission to perform a single-arm, open-label...

California’s legislature could soon be discussing a new bill meant to decriminalize psychedelic substances. On Tuesday, State Senator Scott Wiener announced via Twitter his intention to introduce a new bill aimed at pulling back on penalties for the non-commercial use of these drugs, first...